ID   HeLa-BLMr
AC   CVCL_F0BD
RX   PubMed=2450630;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI_22907; Bleomycin.
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
DI   NCIt; C27677; Human papillomavirus-related endocervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=2450630; DOI=10.1002/1097-0142(19880415)61:8<1501::AID-CNCR2820610805>3.0.CO;2-4;
RA   Urade, Masahiro
RA   Sugi, Masakazu
RA   Miyazaki, Tadashi
RT   "Establishment of three bleomycin-resistant human carcinoma cell lines
RT   and their cross-resistance to other antitumor agents.";
RL   Cancer 61:1501-1507(1988).
//